FeesSafety
Pluang+
Home/News Feed/CTX310 gene therapy cuts triglycerides by 63% in severe hypertriglyceridemia patients after one treatment
CRSP
$49.82
-$0.25 -0.50%

CTX310 gene therapy cuts triglycerides by 63% in severe hypertriglyceridemia patients after one treatment

Company Fundamentals
09 Nov 2026, 16:16 WIB
GlobeNewsWire
View Source
Bullish
CTX310 gene therapy cuts triglycerides by 63% in severe hypertriglyceridemia patients after one treatment

CRISPR Therapeutics presented Phase 1b data showing that a single treatment with CTX310, a gene editing therapy, reduced ANGPTL3 protein by 65% and triglycerides by 63% at 30 days in patients with severe hypertriglyceridemia. The treatment was well tolerated with no serious side effects, offering a promising one-time therapy for patients with high triglycerides who are at risk of pancreatitis and cardiovascular disease. Ongoing trials are further evaluating CTX310's safety and effectiveness across multiple lipid disorders.

CRISPR Therapeutics AG (CRSP) shares are stable, trading at USD 50.07 with no change in the last day on Pluang. This data snapshot is as of Nov 09, 2026 21:31 WIB.

More News (CRSP)

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
23 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App